KRTL Biotech Launches Nutraceuticals Initiative in Partnership with SIGMA and Bolivian Health Programs

KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company") is pleased to announce that its majority-owned subsidiary, KRTL Biotech, Inc., plan to lead a targeted initiative to expand its nutraceuticals portfolio as part of its recently completed merger with Industria Químico Farmacéutica SIGMA Corp SRL ("SIGMA").

SIGMA brings more than 50 years of pharmaceutical manufacturing and commercialization experience, including a strong commitment to preventive care, functional health products, and vitamin-based therapeutics. This initiative is designed to align with government-supported wellness programs in Bolivia and support international market entry strategies for select nutraceuticals.

"The global shift toward preventive care and wellness-focused health interventions makes this a critical moment to expand our nutraceuticals capabilities," said Patricia Wilstermann, CEO of SIGMA. "We are proud to contribute decades of know-how and our product development legacy to a cause that supports both community health and commercial innovation."

Product Scope and Strategic Objectives

KRTL Biotech and SIGMA will focus on a range of vitamin supplements, functional blends, and wellness-oriented therapies that address nutritional gaps across pediatric, prenatal, adult, and geriatric populations. These formulations are manufactured under GMP-compliant protocols and supported by SIGMA’s regulatory expertise.

Initial targets for expansion include:

• Multivitamin blends for immune support and nutritional balance

• Vitamin and mineral formulations tailored for prenatal and senior care

• Functional ingredient products that support cognitive, digestive, and cardiovascular health

• Herbal and natural extracts used in traditional and integrative medicine

These products are already established in Bolivian markets and will be evaluated for export, registration, and regulatory alignment in select Latin American and U.S. jurisdictions.

"This initiative reinforces KRTL Biotech’s commitment to supporting community-based health outcomes through quality, access, and education," said Daniel Bishop, CEO of KRTL Biotech. "We are proud to begin the next phase of innovation with our SIGMA partners."

Community Impact and Global Vision

In Bolivia, SIGMA’s nutraceutical products are being deployed through national wellness campaigns aimed at sustainable, long-term health outcomes. The company collaborates with public health institutions and medical professionals to deliver accessible, science-backed solutions.

KRTL Biotech aims to amplify this success model in broader markets, using SIGMA’s established track record to launch a scalable wellness platform across Latin America and eventually North America.

About KRTL Holding Group, Inc.

KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.

About KRTL Biotech, Inc.

KRTL Biotech, Inc. focuses on building scalable life-science operations that prioritize quality, compliance, and innovation. The company aims to expand its international footprint while maintaining rigorous U.S. reporting and regulatory standards.

About Industria Químico Farmacéutica SIGMA Corp SRL

SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.

For more information:

www.krtlholding.com | www.krtl-icc.com | www.krtlbiotech.com | www.sigmacorp.com.bo/en/about

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. These risks and uncertainties include, but are not limited to, changes in regulatory requirements, market conditions, and other factors described in the Company’s filings. Additional information concerning risks and uncertainties that could materially affect KRTL’s business and financial results is included in the Company’s filings with the OTC Markets and, where applicable, the SEC. You should not place undue reliance on forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.